|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2006-1-24
|
|
pubmed:abstractText |
Raynaud disease (RD) is a common disorder affecting 3% to 5% of the healthy population, and occurs in more than 90% of patients with connective tissue diseases. The therapeutic options remain limited, particularly in patients with secondary RD due to connective tissue disease. Theoretical considerations lead to the expectation that phosphodiesterase type 5 inhibitors may improve clinical symptoms and digital blood flow in patients with RD.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0003-9926
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
23
|
|
pubmed:volume |
166
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
231-3
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16432094-3',5'-Cyclic-GMP Phosphodiesterases,
pubmed-meshheading:16432094-Adult,
pubmed-meshheading:16432094-Blood Flow Velocity,
pubmed-meshheading:16432094-Cyclic Nucleotide Phosphodiesterases, Type 5,
pubmed-meshheading:16432094-Dose-Response Relationship, Drug,
pubmed-meshheading:16432094-Drug Administration Schedule,
pubmed-meshheading:16432094-Female,
pubmed-meshheading:16432094-Follow-Up Studies,
pubmed-meshheading:16432094-Humans,
pubmed-meshheading:16432094-Laser-Doppler Flowmetry,
pubmed-meshheading:16432094-Male,
pubmed-meshheading:16432094-Middle Aged,
pubmed-meshheading:16432094-Patient Satisfaction,
pubmed-meshheading:16432094-Phosphodiesterase Inhibitors,
pubmed-meshheading:16432094-Phosphoric Diester Hydrolases,
pubmed-meshheading:16432094-Pilot Projects,
pubmed-meshheading:16432094-Probability,
pubmed-meshheading:16432094-Raynaud Disease,
pubmed-meshheading:16432094-Risk Assessment,
pubmed-meshheading:16432094-Severity of Illness Index,
pubmed-meshheading:16432094-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease.
|
|
pubmed:affiliation |
Klinik III für Innere Medizin, Universität zu Köln, Köln, Germany.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, Non-U.S. Gov't
|
